What was announced
On February 6, 2024, Elemind announced that it had emerged from stealth with $12 million in seed funding to develop its neurotechnology business and first product. The round is described as seed funding in the company’s announcement—not a Series B.
What this source establishes
This is a company-issued press release distributed by Business Wire. It supports the announced amount, round and date. It is not independent evidence that a device improves sleep or treats insomnia.
What we corrected
Our archive previously included an unsupported $32 million Series B story. We have withdrawn it. We also removed claims about FDA plans and future trials that the cited seed announcement did not establish. This historical record does not assert that no later financing occurred.